smithkline ltskb aim 10 pct earning raise smithkline beckman corp pursue threepoint stragey achieve 10 pct annual increase operate earning remainder decade 1986 smithkline earn 5211 mln dlrs 678 dlrs share revenue 36 billion dlrs company annual report nonpharmaceutical business play major role meet earning growth target fact grow fast pharmaceutical business smithkline major product antiulcer medication tagamet report intend improve earning exist product expand product portfolio optimize financial resource bolster position antiulcer market tagamet meet stiff competition smithkline strategy develop overthecounter version tagamet bolster joint venture ltwellcome plc pende venture japan smithkline allergan eye skin care product division billion dlr organization year grow 10 pct annually nondilutive acquisition real possibility gavin herbert president eye skin care product group report 1986 allergan worldwide sale 433 mln dlrs smith kline french laboratories pharmaceuticals unit 1986 sale 19 billion dlrs file food drug administration marketing approval number cardiovascular agent include tissue plasminogen activator year sk fs us sale force 20 pct large 1987 1000 sale personnel smith kline small clinical laboratory testing unit 1986 sale 373 mln dlrs perform 24 mln test year see increase employee drug testing testing aids antibody smith kline depend share price cost money buy back share year buy back 25 pct share smithkline begin year management team include chief operating officer george ebright